MedTrace Logo

NAD Supplementation in Parkinson's Disease

NCT07703137 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-08-12

No results posted yet for this study

Summary

The goal of this clinical trial is to learn whether Nicotinamide Riboside, a form of Vitamin B3 also known as NR, can improve blood vessel health in the brain, memory, and physical function in eligible study participants. NR is considered investigational for this study because it is not yet established for this specific use.

The main questions it aims to answer are:

Can NR improve non-invasive measures of blood vessel health in the brain? Can NR improve memory testing results and physical function?

Researchers will compare participants who receive NR with participants who receive a placebo, an inactive substance that looks like the study drug, to see if NR has beneficial effects. Participants will be randomly assigned to receive either NR or placebo.

They will complete 3 study visits over 13 weeks at the Translational Geroscience Laboratory at the University of Oklahoma Health Campus. During the visits, participants will complete questionnaires, memory testing, non-invasive blood vessel measurements, physical function tests, and a blood draw.

Conditions

Interventions

DIETARY_SUPPLEMENT

Nicotinamide Riboside (NR)

Participants will be randomized to receive either oral nicotinamide riboside at a total daily dose of 1 g or an identically appearing placebo for 12 weeks.

DIETARY_SUPPLEMENT

Oral placebo capsules

1 g identically appearing placebo capsule

Sponsors & Collaborators

  • Presbyterian Health Foundation

    collaborator OTHER

  • University of Oklahoma

    lead OTHER

Principal Investigators

  • Andriy Yabluchanskiy, MD, PhD · University of Oklahoma Health Campus

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
55 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-08-10
Primary Completion
2027-07-31
Completion
2027-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07703137 on ClinicalTrials.gov